Aperio Group LLC Has $1.07 Million Holdings in Alkermes PLC (ALKS)
Aperio Group LLC reduced its position in Alkermes PLC (NASDAQ:ALKS) by 17.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,981 shares of the company’s stock after selling 4,459 shares during the quarter. Aperio Group LLC’s holdings in Alkermes PLC were worth $1,067,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank grew its holdings in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the last quarter. Greenwood Capital Associates LLC grew its holdings in Alkermes PLC by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after purchasing an additional 41 shares during the last quarter. US Bancorp DE grew its holdings in shares of Alkermes PLC by 366.4% during the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after buying an additional 3,122 shares during the last quarter. Insight Capital Research & Management Inc. purchased a new stake in shares of Alkermes PLC during the second quarter valued at $232,000. Finally, Aviance Capital Partners LLC purchased a new stake in shares of Alkermes PLC during the second quarter valued at $232,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.
Shares of Alkermes PLC (ALKS) opened at $48.40 on Friday. Alkermes PLC has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The firm’s revenue was up 20.6% on a year-over-year basis. equities research analysts forecast that Alkermes PLC will post -0.59 EPS for the current year.
A number of equities research analysts have recently weighed in on the stock. ValuEngine lowered shares of Alkermes PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Barclays PLC set a $50.00 price objective on shares of Alkermes PLC and gave the company a “hold” rating in a report on Thursday, October 26th. Citigroup Inc. set a $62.00 price objective on shares of Alkermes PLC and gave the company a “hold” rating in a report on Thursday, October 26th. Credit Suisse Group dropped their price objective on shares of Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.55.
In other Alkermes PLC news, SVP James M. Frates sold 20,932 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard F. Pops sold 50,000 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total transaction of $2,443,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,498 shares of company stock worth $5,018,010. 5.34% of the stock is owned by corporate insiders.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.